Publications | Venatorx Pharmaceuticals

Publications

News

Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen

July 27, 2020

Venatorx Pharmaceuticals Named ‘Best Places to Work’ Third Year in a Row

June 30, 2020

> See all News

Manuscripts

VNRX-5133 (Taniborbactam), a broad-spectrum inhibitor of serine- and metallo-beta-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa

Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-beta-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections

>> More Manuscripts

Posters

Rescue of Ceftibuten Activity by the Oral Beta-Lactamase Inhibitor VNRX-7145 against Enterobacteriaceae Expressing Class A, C and/or D Beta-Lactamases.

Evaluation of the in vitro activity of cefepime plus taniborbactam (formerly VNRX-5133) and comparative agents against carbapenem-resistant Enterobacteriaceae.

Oral ceftibuten/VNRX-7145 shows equivalent activity in vitro to IV therapeutics against MDR Enterobacteriaceae.

Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) Broad-Spectrum Activity is Maintained against Emerging KPC- and PDC-Variants in Multidrug Resistant K. pneumoniae and P. aeruginosa.

>> More Posters